Fig. 5.
HIV-1 restriction by A3H haplotype II splice variants and SV200 processing by HIV-1 protease. a Infectivity of Vif-deficient HIV-1LAI produced in 293T cells in the presence of untagged A3H splice variants (50 ng, 100 ng, 200 ng, or 400 ng) or V5-tagged A3G (25 ng, 50 ng, 100 ng, or 200 ng) and used to infect CEM-GFP reporter T cells (n = 3 technical replicates; average ± SD). Immunoblots are shown below for producer cells and virus-like particles (VLPs). b Infectivity of Vif-deficient HIV-1LAI produced in 293T cells in the presence of a control vector (no A3) or the indicated untagged A3H splice variants (200 ng). HIV-1 protease inhibitors (0.3 nM, 3 nM, or 300 nM) darunavir (DRV) or atazanavir (AZV) were added 6 h post-transfection or 42 h before virus particle collection, virus infectivity assays using CEM-GFP reporter cells, and VLP and cell lysate immunoblotting as in (a). c Immunoblots of A3H haplotype II SV200 and mutant derivatives in VLPs, following production in 293T cells. Gag (p24) is shown as a loading control. d Immunoblots of A3H haplotype II SV183 and SV200 in VLPs from the indicated proviral plasmids, following production in 293T cells. Gag (p24 for HIV-1 isolates and p27 for SIVmac239) is shown as a loading control